Wacker Chemie AG has officially opened its WACKER Biotechnology Center in Munich. The company has invested a double-digit million-euro sum in the facility.

“The Wacker Biotech Center will allow us to concentrate and intensify our biotech research activities. We see tremendous growth potential in this area, which is why we have decided to go ahead and invest in this sector – even in economically challenging times,” highlighted Wacker CEO Christian Hartel at the opening ceremony.

“With the new Biotechnology Center, Wacker is not only securing high-quality jobs, but also strengthening Bavaria’s expertise in biotechnology. This demonstrates a strong commitment to Bavaria as a business location, and is exactly the kind of project we need to ensure our competitiveness and bring innovations from Bavaria to the world,” affirmed Bavarian Minister of Economic Affairs Hubert Aiwanger at the opening ceremony.

The Wacker Biotechnology Center is integrated into the group’s research site in the Munich quarter of sendling where the company has been conducting fundamental research for over a century and, since the 1980s, also in biotechnology. With the expansion of the biotechnology business, it was evident that Wacker’s research capacities had reached their limits. With space for around 90 employees and state-of-the-art equipment, the Wacker Biotechnology Center opens new doors.

Spread over four floors, the new building is home to Wacker’s research operations, including methods to manufacture biopharmaceuticals, the medicines of tomorrow. The focus will be on processes for the production of proteins and nucleic acids, which play an important role in developing innovative therapies involving, for example, active ingredients based on messenger ribonucleic acid (mRNA).

In addition, Wacker is committed to developing innovative ingredients for food and dietary supplements that contribute to healthy and sustainable nutrition for the generations of today and the future.